Peptides for chronic fatigue FAQ

MOTS-c and Selank show measurable effects within 1–3 weeks, making them better candidates for short-duration studies than TB-4, which requires four weeks minimum for mitochondrial density changes to manifest. If ATP output is the primary endpoint and timeline is constrained, MOTS-c is the stronger choice. It acts on existing mitochondria rather than inducing biogenesis.

MOTS-c demonstrates the strongest evidence in aged-animal fatigue models. A 2022 study in 18-month-old mice (equivalent to ~60-year-old humans) showed MOTS-c restored exercise capacity to levels comparable to young controls, whereas TB-4 studies have primarily used young-adult animals. Age-related mitochondrial dysfunction involves impaired Complex I activity specifically. MOTS-c targets that defect directly.

Combine a mitochondrial-targeting peptide (TB-4 or MOTS-c) with Selank in separate treatment arms or as a co-administration protocol. Preclinical fatigue models that measure both forced swim performance (central fatigue) and ATP content (peripheral fatigue) benefit from addressing both neuroinflammatory and bioenergetic pathways simultaneously. Co-administration hasn't been formally studied, but the mechanisms don't overlap. One acts on electron transport chains, the other on cytokine signaling.

This can occur with immune-modulating peptides like Thymalin or KPV as the immune system recalibrates from a chronically activated state. The temporary symptom intensification (often 3–7 days) reflects cytokine shifts during the transition from pro-inflammatory to regulatory dominance. If fatigue worsens beyond 10 days or is accompanied by fever or lymph node swelling, stop the protocol and consult your supervising physician. This may indicate an underlying infection that requires different management.

Start by confirming you're addressing the correct mechanism. Supplements provide substrates (CoQ10, B vitamins, magnesium). Peptides regulate the cellular machinery that uses those substrates. If your mitochondria can't properly assemble electron transport complexes, more CoQ10 won't help. AMPK-modulating peptides or thymic regulators work at the signalling level, which is why they produce effects when substrate supplementation fails. Expect a 4–8 week timeline for meaningful response, not the immediate effect stimulants provide.

Reassess your working diagnosis. Chronic fatigue syndrome shares symptoms with hypothyroidism, sleep apnoea, anaemia, and chronic infections. All of which require different interventions. Peptides targeting mitochondrial or immune dysfunction won't correct an undiagnosed thyroid disorder. Get baseline labs (TSH, free T3/T4, ferritin, comprehensive metabolic panel, inflammatory markers) before concluding a peptide protocol failed. If labs are normal and peptides produced no effect, the issue may be peptide quality. Degraded or contaminated peptides have zero biological activity.

Introduce one peptide at a time with at least 2–3 weeks between additions. Track objective metrics. Not just subjective fatigue ratings. Use heart rate variability (HRV) via wearable devices, sleep stage data, or cognitive testing apps to quantify changes. Growth hormone secretagogues should improve deep sleep within 7–10 days; immune peptides may take 3–4 weeks to show measurable cytokine changes. If you stack peptides simultaneously, you lose the ability to isolate which mechanism is driving improvement.

Reduce the dose by 50% and split into twice-daily administration. Dihexa's HGF receptor binding can trigger rapid synaptic remodeling that outpaces glial support cell adaptation. Manifesting as headaches, sensory sensitivity, or sleep disruption. A slower titration (starting at 0.25mg/kg and increasing weekly) allows astrocyte and oligodendrocyte populations to scale alongside neuronal changes. If symptoms persist below threshold dose, Dihexa may not be appropriate for that patient's current neural substrate.

Administer zinc picolinate (30mg daily) for two weeks before initiating Thymalin. Thymulin. The peptide hormone Thymalin helps restore. Requires zinc as a structural cofactor for receptor binding. Patients with serum zinc below 80 mcg/dL show blunted T-regulatory cell response and minimal IL-6 reduction even at standard Thymalin doses. The two-week saturation window allows hepatic zinc stores to normalize before introducing the thymic peptide.

Extend the protocol to eight weeks (20 sessions total) and verify NAD+ cofactor status. Mitochondrial biogenesis requires NAD+ as an electron carrier. Patients with depleted NAD+ pools (common in chronic illness) can't synthesize new mitochondria regardless of PGC-1α upregulation. Nicotinamide riboside (300mg daily) or NMN (500mg daily) supplementation addresses this substrate bottleneck. If no improvement occurs by session 20, mitochondrial dysfunction may not be the primary driver of cognitive symptoms.

Mitochondrial peptides denature rapidly above 8°C. MOTS-C loses approximately 15–20% activity per 24 hours at room temperature post-reconstitution according to stability data. If shipping temperature exceeded 8°C for more than 12 hours, the peptide should not be used in research. There's no at-home test for potency loss. Appearance and clarity don't change when peptides denature. Research protocols should include temperature loggers with all shipments and document any excursions as protocol deviations.

Mitochondrial peptides can temporarily increase ROS production as oxidative phosphorylation ramps up before antioxidant systems adapt. This is mechanistically expected with MOTS-C and should resolve by week 3–4. If symptoms persist beyond four weeks, the peptide is either impure (contaminants causing inflammation) or the subject has an undiagnosed condition where increased metabolic demand worsens symptoms (severe adrenal insufficiency, untreated hypothyroidism). Discontinue and evaluate thyroid function, cortisol, and inflammatory markers before resuming.

This pattern indicates receptor-based mechanisms rather than mitochondrial restoration. Growth hormone secretagogues consistently produce this curve. Initial energy improvement as IGF-1 rises, followed by plateau as ghrelin receptors downregulate. Switch to mitochondrial-targeting peptides (MOTS-C, SS-31) or add humanin to address oxidative stress if the initial response suggests the pathway was relevant but tolerance developed. Research protocols experiencing this should measure receptor density at baseline and week 8 to quantify desensitisation.

This dissociation suggests neuronal mitochondrial function improved (Semax effect on CNS) while skeletal muscle mitochondria remained dysfunctional. Add MOTS-C or consider that the fatigue aetiology is primarily neurological rather than metabolic. Research designs should track cognitive and physical fatigue as separate endpoints. Compounds like Semax won't improve six-minute walk distance but will improve sustained attention tasks.

Discard it. There's no reliable way to assess remaining potency at home. Peptides degrade through oxidation and structural denaturation at ambient temperature, and the degradation is irreversible. A vial left at 22°C for 8–12 hours may retain 50–70% activity, but you cannot dose accurately when the concentration is unknown. The cost of replacing a vial is lower than continuing a protocol with subtherapeutic dosing and attributing lack of results to peptide inefficacy rather than handling error.

Resume at the next scheduled dose. Do not double-dose to

First, verify preparation and storage: peptides stored above 8°C or reconstituted incorrectly lose potency. Second, confirm dosing accuracy. Underdosing is common with peptides requiring precise micrograms per injection. Third, assess whether the peptide matches the mechanism: Thymalin won't improve fatigue driven by mitochondrial dysfunction, and MK-677 won't correct immune dysregulation. If preparation and dosing are correct but no improvement occurs, the underlying cause may require a different peptide category or combination therapy. Some patients respond best to stacked protocols. Thymalin for immune restoration plus MK-677 for recovery optimisation.

Start by identifying the pattern: fatigue worsened after a viral illness or autoimmune diagnosis suggests immune dysregulation (Thymalin). Fatigue paired with brain fog, memory issues, or post-concussion symptoms suggests neurotrophic support (Cerebrolysin or Dihexa). Fatigue with poor exercise recovery, low muscle mass, or disrupted sleep suggests GH deficiency (MK-677 or CJC-1295/Ipamorelin). Blood work can confirm: low NK cell counts or elevated inflammatory markers point to immune peptides; low IGF-1 or poor sleep quality points to GH secretagogues. Working with a prescriber who understands peptide mechanisms is essential. Starting the wrong category wastes time and delays improvement.

Continue the protocol through week 8 before evaluating efficacy. Thymic regeneration and T-cell population shifts take 6–8 weeks to produce subjective fatigue reduction. Immune modulation is slower than metabolic or hormonal interventions. If blood markers (IL-6, hs-CRP) haven't decreased by week 8, the fatigue may not be immune-driven. Switch focus to mitochondrial support with MK 677 or metabolic compounds, and retest baseline cortisol and thyroid panels to rule out HPA axis dysfunction or subclinical hypothyroidism.

MK-677 and CJC-1295/Ipamorelin stimulate endogenous GH release, which may be redundant or suppressive if you're on exogenous GH replacement. Combining them requires careful monitoring of IGF-1 levels to avoid supraphysiological ranges, which increase the risk of insulin resistance and joint pain. Thymalin and Cerebrolysin, however, work through entirely different pathways and can be safely combined with GH therapy. The key is understanding that peptides are mechanism-specific tools. Stacking peptides that target the same pathway provides diminishing returns, while stacking peptides that address different mechanisms can produce synergistic benefits.